Identification of chromosomal abnormalities in prostate cancer by array CGH Free

LB-55

Genetic alterations are the hallmark for various diseases like cancer, mental retardation and birth defects. Identifying these alterations and the genes they contain will provide molecular targets for diagnosis and therapy.

Genomic DNA was isolated from LNCaP, a human prostate cancer model cell line. Labeled genomic DNA probes were generated from LNCap cells and normal female genomic DNAs using CyScribe™ Array CGH Genomic Labeling Kit (GE Helathcare) and BioPrime™ Array CGH Genomic Labelling System (Invitrogen). The labeled fragments were hybridized on to a Spectral Chip™ 2600 used for whole genome scanning and Constitutional Chip™ 3.0 containing clones for 48 constitutive diseases. Image analysis was performed by Axxon GenePix^® Pro 6.0 software and chromosomal abnormalities were identified using web-based Spectral Ware™. Higher dye labeled DNA yields (>16%) and CyDye dCTP-nucleotide incorporation (10%) were achieved with Amersham CyScribe Array CGH Genomic Labeling Kit. Analysis of hybridization data showed similar signal intensities, log₂ ratios and signal to noise ratios for the two kits. Both kits identified loss in 2p22.3-2p14; 10q23.1-10q24.33; 13q21.1-13q22.1 chromosomal regions and strong gain in Yq11.2 region that were previously detected by conventional CGH.